Immunovant/$IMVT
1D1W1MYTD1Y5YMAX
Capital at risk
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
- Ticker
- $IMVT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 315
- Headquarters
- Durham, United States
- Website
- immunovant.com
Immunovant Metrics
BasicAdvanced
$6.9B
-
-$2.82
0.81
-
Price and volume
Market cap
$6.9B
Beta
0.81
52-week high
$45.42
52-week low
$15.56
Average daily volume
1.4M
Financial strength
Current ratio
7.269
Quick ratio
6.819
Profitability
EBITDA (TTM)
-565.607
Effective tax rate (TTM)
0.13%
Management effectiveness
Return on assets (TTM)
-46.73%
Return on equity (TTM)
-80.10%
Valuation
Price to book
9.34
Price to tangible book (TTM)
9.34
Price to free cash flow (TTM)
-15.359
Free cash flow yield (TTM)
-6.51%
Free cash flow per share (TTM)
-2.168
Growth
Earnings per share change (TTM)
-0.66%
3-year earnings per share growth (CAGR)
13.39%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Analyst projections of the future price of Immunovant stock.
Bulls say / Bears say
IMVT-1402 produced encouraging early results in difficult-to-treat rheumatoid arthritis, with Week 16 ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8%. No new drug-related safety signals were identified, although the data came from an open-label period. (Immunovant)
The same asset is being advanced across six autoimmune indications, with potentially registrational Graves’ disease and myasthenia gravis readouts expected in 2027 and CIDP and Sjögren’s disease data expected in 2028. This gives successful development in one indication the potential to support a broader multi-product franchise. (Immunovant)
Immunovant reported $797.8 million of cash and cash equivalents at 30 June 2026, which it believes provides runway to a potential Graves’ disease launch. That reduces the immediate need for a dilutive capital raise while several important clinical catalysts are still ahead. (Immunovant)
IMVT-1402 failed to achieve statistical significance on the primary endpoint in its 57-patient cutaneous lupus trial, and Immunovant is stopping development in that indication. The result weakens confidence that the FcRn mechanism will translate consistently across autoimmune diseases. (GlobeNewswire)
Immunovant has also discontinued batoclimab after two Phase 3 thyroid eye disease trials missed their primary endpoint, incurring $39 million in contractual costs. The failure highlights clinical and commercial risk for a company whose second-generation drug remains unapproved. (Fierce Biotech)
The company is loss-making and spending heavily to advance a single lead programme: quarterly R&D expense rose to $142.6 million and net loss reached $153.2 million. Its $797.8 million cash balance is expected to fund only the potential Graves’ disease launch, not development and commercialisation across every planned indication, increasing longer-term financing and dilution risk. (Immunovant, Immunovant)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunovant News
AllArticlesVideos
Funds containing Immunovant
AllUSDGBPEUR
Fund name | Fund size | $IMVT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.46% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.46% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.